Trigeminal Neuralgia (Tic Douloureux) (Central Nervous System) - Drugs In Development, 2021
posters feature data from the Phase III trials and the long-term safety study of rimegepant as an acute treatment for migraine, including in people who have a history of treatment failure with triptans. [...] The poster presentations are entitled as Rapid Decrease in Migraine Days with Rimegepant: Results from a Post hoc Analysis of a Phase II/III, Randomized, Double-Blind, Placebo-Controlled Trial", Long-term Use of Rimegepant ## mg for the Acute Treatment of Migraine Reduces Use of Analgesics and Antiemetics", Rimegepant for the Acute Treatment of Migraine: Subgroup Analyses From ## Phase III Clinical Trials by Number of Triptans Previously Tried and Failed", "An Open-label, Intermediate- size, Expanded Access Protocol of Rimegepant in the Acute Treatment of Migraine", Rimegepant ## mg for the Acute Treatment of Migraine in Adults With Frequent Migraine: Long-Term Safety and Clinical Improvement Versus Baseline", Long-Term Safety of Rimegepant ## mg for the Acute Treatment of Migraine in Adults With a History of Triptan Treatment Failure", Acute Treatment with Oral Rimegepant ## mg Reduces Migraine-Related Disability in Adults With and Without a History of Triptan Treatment Failure: Results from a One Year, Open-Label Safety Study", Acute Treatment of Migraine With Rimegepant Improves Health Related Quality of Life in Adults With a History of Triptan Treatment Failure: Results from a Long-Term, Open-Label Safety Study", Preference for Rimegepant and Improved Clinical Global Impression of Change Among Adults With a History of Triptan Treatment Failure: Results from a Long-Term Open-Label Safety Study", Monthly Migraine Days, Tablet Utilization, and Quality of Life Associated with Rimegepant - Post Hoc Results from an Open Label Safety Study (BHV3000-##)", Rimegepant ## mg, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm", Acute Treatment with Rimegepant ## mg Confers Long Term Improvements in Median Time to ## percent and ## percent Reductions in Monthly Migraine Days - Post Hoc Results from an Open Label Safety Study (BHV3000-##)", Rimegepant Versus Atogepant and Monoclonal Antibody Treatments for the Prevention of Migraine: A Systematic Literature Review and Network Meta- analysis". [...] Subgroup analyses of triptan failure from the rimegepant clinical trials in the acute treatment of migraine demonstrated treatment with rimegepant up to once daily over one year improved migraine- related disability in subjects who had previously failed ## or greater than or equal to ## triptans and in those who had no history of triptan treatment failure.